Bone health care in women with breast cancer.

The objective is to provide a sound pathophysiological background along with evidence-based and practical recommendations for physicians managing such women. PMID: 31853818 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research

Related Links:

This study is the first to provide a direct link between this inflammation and plaque development - by way of IFITM3. Scientists know that the production of IFITM3 starts in response to activation of the immune system by invading viruses and bacteria. These observations, combined with the new findings that IFITM3 directly contributes to plaque formation, suggest that viral and bacterial infections could increase the risk of Alzheimer's disease development. Indeed, researchers found that the level of IFITM3 in human brain samples correlated with levels of certain viral infections as well as with gamma-secretase activ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Trifu SC, Istrate D, Miruna DA Abstract Schizophrenia is considered the most severe and debilitating psychiatric disorder. During the 80's, first reports on abnormalities of the schizophrenic brain which could be objectively observed on MRI, CT scans and other imagistic techniques were published. This showed that schizophrenia is a disorder that goes beyond the functional aspect of the symptomatology. The ties between psychiatry and endocrinology are easily observed, even empirically, by any mental health practitioner, and mirrored by endocrinology specialists. Disorders related to menstruation phase of th...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Reports from the Women ’s Health Initiative (WHI), first published in 2002, have informed and complicated the narrative of the relative benefits and potential harms of menopausal hormone therapy (HT) over the past 20 years. Prior to the initiation of the WHI trials, hormone therapy had already experienced a tumultuous p ublic stature. Initially heralded as the cure for menopause in the 1960s, unopposed estrogen therapy was vilified when its association with increased risk of endometrial hyperplasia and cancer emerged. The discovery that the addition of progesterone to estrogen therapy mitigated this risk propelled ho...
Source: JAMA - Category: General Medicine Source Type: research
We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovas...
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
CONCLUSIONS: Hormone replacement therapy may slightly improve overall survival in women who have undergone surgical treatment for EOC, but the certainty of the evidence is low. HRT may make little or no difference to quality of life, incidence of breast cancer, TIA, CVA and MI as the certainty of the evidence has been assessed as very low. There may be little or no effect of HRT use on progression-free survival. The evidence in this review is limited by imprecision and incompleteness of reported relevant outcomes and therefore the results should be interpreted with caution. Future well-designed RCTs are required as this is...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
AbstractPurpose of ReviewThe goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause.Recent FindingsEstrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle an...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Menopausal hormone therapy (MHT) is the treatment of choice for menopausal symptoms and urogenital atrophy. Furthermore, it has beneficial effects on chronic diseases related to estrogen deficiency, such as osteoporosis and cardiovascular disease [1 –4]. Women worldwide have been using MHT to alleviate their symptoms for decades. However, fear of breast cancer, hinders menopausal women from seeking medical advice and renders clinicians reluctant to prescribe MHT.
Source: Maturitas - Category: Primary Care Authors: Source Type: research
ConclusionsThe natural, age-related reduction in bone density is exacerbated by breast cancer active AI treatment. Future research should focus on investigating screening adherence-related barriers/facilitators and effective strategies to bring practice in line with agreed standards.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
Our panel this morning discussed the issues surrounding how the WHI results were interpreted and communicated to women and their health care providers. We recognize that hormones are not appropriate for all women, and look forward to hosting a future panel that highlights alternatives. The speakers have a variety of backgrounds and experiences (and genders), and we aim to promote diversity of voices. This was not normal breakfast conversation. Today was a jolting – and disruptive – talk about what happens to women’s bodies when they age. (Who knew that if you’re menopausal and you don’t take y...
Source: Disruptive Women in Health Care - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
Conclusions: Choice of SERM, selection of doses, and clinical trial data evaluating safety and efficacy are key to ensuring safety and adequate therapeutic effect of TSECs for addressing menopausal symptoms.
Source: Menopause - Category: OBGYN Tags: Clinical Corner: Invited Review Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrinology | Health Management | Hormonal Therapy | Hormones | Men | Menopause | Orthopaedics | Osteoporosis | Women